Another intriguing example of CpG-mediated anti-tumour effect was reported afterintratumoural injection of the TLR9 agonist CpG, along with anti-OX40Land/or anti-CTLA4 antibodies, to eliminate TREGs in the tumourmicroenvironment. Here, CTLA4 is linked to neoplasm.